Extension program for Bay 43-9006 [sorafenib].

Trial Profile

Extension program for Bay 43-9006 [sorafenib].

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Cancer
  • Focus Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 25 Mar 2009 Actual patient number (400) added as reported by ClinicalTrials.gov.
    • 06 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top